Repositioning Candidate Details
| Candidate ID: | R0471 |
| Source ID: | DB08816 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Ticagrelor |
| Synonyms: | |
| Molecular Formula: | C23H28F2N6O4S |
| SMILES: | CCCSC1=NC2=C(N=NN2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)C(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=N1 |
| Structure: |
|
| DrugBank Description: | Ticagrelor, marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU, is a platelet aggregation inhibitor. It is not a prodrug like clopidogrel. The drug was approved for use in the European Union on 3 December 2010 and was given FDA approval on 20 July 2011. |
| CAS Number: | 274693-27-5 |
| Molecular Weight: | 522.568 |
| DrugBank Indication: | Ticagrelor is indicated for the prevention of thrombotic events like stroke or heart attack in patients with acute coronary syndrome or myocardial infarction with ST elevation. |
| DrugBank Pharmacology: | Plasma concentrations of ticagrelor are higher in the elderly, women, patients of Asian ethnicity, and those with hepatic impairment. Plasma concentrations are decreased in patients with darker skin and those with severe renal impairment. Japenese patients have 40% higher plasma concentrations than Caucasian patients. This difference decreases to 20% when corrections for body weight are made. Ticagrelor has not been tested in severe hepatic impairment. |
| DrugBank MoA: | Ticagrelor is a reversible allosteric antagonist of P2Y12. This prevents ADP binding to the P2Y12 receptor. Because it is not a prodrug, it may be of use to patients who are poor metabolizers as they may not receive as much benefit from a prodrug. |
| Targets: | P2Y purinoceptor 12 |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|